Literatura académica sobre el tema "Nanocarrier Liposoma"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Nanocarrier Liposoma".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Nanocarrier Liposoma"
1
Marqués-Gallego, Patricia y Anton I. P. M. de Kroon. "Ligation Strategies for Targeting Liposomal Nanocarriers". BioMed Research International 2014 (2014): 1–12. http://dx.doi.org/10.1155/2014/129458.
Texto completoResumen
Liposomes have been exploited for pharmaceutical purposes, including diagnostic imaging and drug and gene delivery. The versatility of liposomes as drug carriers has been demonstrated by a variety of clinically approved formulations. Since liposomes were first reported, research of liposomal formulations has progressed to produce improved delivery systems. One example of this progress is stealth liposomes, so called because they are equipped with a PEGylated coating of the liposome bilayer, leading to prolonged blood circulation and improved biodistribution of the liposomal carrier. A growing research area focuses on the preparation of liposomes with the ability of targeting specific tissues. Several strategies to prepare liposomes with active targeting ligands have been developed over the last decades. Herein, several strategies for the functionalization of liposomes are concisely summarized, with emphasis on recently developed technologies for the covalent conjugation of targeting ligands to liposomes.
2
Nikolova, Maria P., Enamala Manoj Kumar y Murthy S. Chavali. "Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment". Pharmaceutics 14, n.º 10 (15 de octubre de 2022): 2195. http://dx.doi.org/10.3390/pharmaceutics14102195.
Texto completoResumen
Liposomes are well-known nanoparticles with a non-toxic nature and the ability to incorporate both hydrophilic and hydrophobic drugs simultaneously. As modern drug delivery formulations are produced by emerging technologies, numerous advantages of liposomal drug delivery systems over conventional liposomes or free drug treatment of cancer have been reported. Recently, liposome nanocarriers have exhibited high drug loading capacity, drug protection, improved bioavailability, enhanced intercellular delivery, and better therapeutic effect because of resounding success in targeting delivery. The site targeting of smart responsive liposomes, achieved through changes in their physicochemical and morphological properties, allows for the controlled release of active compounds under certain endogenous or exogenous stimuli. In that way, the multifunctional and stimuli-responsive nanocarriers for the drug delivery of cancer therapeutics enhance the efficacy of treatment prevention and fighting over metastases, while limiting the systemic side effects on healthy tissues and organs. Since liposomes constitute promising nanocarriers for site-targeted and controlled anticancer drug release, this review focuses on the recent progress of smart liposome achievements for anticancer drug delivery applications.
3
Yan, Wei, Sharon SY Leung y Kenneth KW To. "Updates on the use of liposomes for active tumor targeting in cancer therapy". Nanomedicine 15, n.º 3 (febrero de 2020): 303–18. http://dx.doi.org/10.2217/nnm-2019-0308.
Texto completoResumen
In the development of cancer chemotherapy, besides the discovery of new anticancer drugs, a variety of nanocarrier systems for the delivery of previously developed and new chemotherapeutic drugs have currently been explored. Liposome is one of the most studied nanocarrier systems because of its biodegradability, simple preparation method, high efficacy and low toxicity. To make the best use of this vehicle, a number of multifunctionalized liposomal formulations have been investigated. The objective of this review is to summarize the current development of novel active targeting liposomal formulations, and to give insight into the challenges and future direction of the field. The recent studies in active targeting liposomes suggest the great potential of precise targeted anticancer drug delivery in cancer therapeutics.
4
Andreana, Ilaria, Valeria Bincoletto, Maela Manzoli, Francesca Rodà, Vita Giarraputo, Paola Milla, Silvia Arpicco y Barbara Stella. "Freeze Drying of Polymer Nanoparticles and Liposomes Exploiting Different Saccharide-Based Approaches". Materials 16, n.º 3 (31 de enero de 2023): 1212. http://dx.doi.org/10.3390/ma16031212.
Texto completoResumen
Biodegradable nanocarriers represent promising tools for controlled drug delivery. However, one major drawback related to their use is the long-term stability, which is largely influenced by the presence of water in the formulations, so to solve this problem, freeze-drying with cryoprotectants has been proposed. In the present study, the influence of the freeze-drying procedure on the storage stability of poly(lactide-co-glycolide) (PLGA) nanoparticles and liposomes was evaluated. In particular, conventional cryoprotectants were added to PLGA nanoparticle and liposome formulations in various conditions. Additionally, hyaluronic acid (HA), known for its ability to target the CD44 receptor, was assessed as a cryoprotective excipient: it was added to the nanocarriers as either a free molecule or conjugated to a phospholipid to increase the interaction with the polymer or lipid matrix while exposing HA on the nanocarrier surface. The formulations were resuspended and characterized for size, polydispersity index, zeta potential and morphology. It was demonstrated that only the highest percentages of cryoprotectants allowed the resuspension of stable nanocarriers. Moreover, unlike free HA, HA-phospholipid conjugates were able to maintain the particle mean size after the reconstitution of lyophilized nanoparticles and liposomes. This study paves the way for the use of HA-phospholipids to achieve, at the same time, nanocarrier cryoprotection and active targeting.
5
Yue, Xiuli y Zhifei Dai. "Liposomal Nanotechnology for Cancer Theranostics". Current Medicinal Chemistry 25, n.º 12 (19 de abril de 2018): 1397–408. http://dx.doi.org/10.2174/0929867324666170306105350.
Texto completoResumen
Liposomes are a type of biomimetic nanoparticles generated from self-assembling concentric lipid bilayer enclosing an aqueous core domain. They have been attractive nanocarriers for the delivery of many drugs (e.g. radiopharmaceuticals, chemotherapeutic agents, porphyrin) and diagnostic agents (e.g. fluorescent dyes, quantum dots, Gadolinium complex and Fe3O4) by encapsulating (or adsorbing) hydrophilic one inside the liposomal aqueous core domain (or on the bilayer membrane surface), and by entrapping hydrophobic one within the liposomal bilayer. Additionally, the liposome surface can be easily conjugated with targeting molecules. Liposomes may accumulate in cancerous tissues not only passively via enhanced permeability and retention (EPR) effect, but also actively by targeting cancer cell or angiogenic marker specifically. The multimodality imaging functionalization of liposomal therapeutic agents makes them highly attractive for individualized monitoring of the in vivo cancer targeting and pharmacokinetics of liposomes loading therapeutic drugs, and predicting therapeutic efficacy in combination with the helpful information from each imaging technique. The present review article will highlight some main advances of cancer theranostic liposomes with a view to activate further research in the nanomedicine community.
6
Tansi, Felista L., Ronny Rüger, Ansgar M. Kollmeier, Markus Rabenhold, Frank Steiniger, Roland E. Kontermann, Ulf K. Teichgräber, Alfred Fahr y Ingrid Hilger. "Targeting the Tumor Microenvironment with Fluorescence-Activatable Bispecific Endoglin/Fibroblast Activation Protein Targeting Liposomes". Pharmaceutics 12, n.º 4 (17 de abril de 2020): 370. http://dx.doi.org/10.3390/pharmaceutics12040370.
Texto completoResumen
Liposomes are biocompatible nanocarriers with promising features for targeted delivery of contrast agents and drugs into the tumor microenvironment, for imaging and therapy purposes. Liposome-based simultaneous targeting of tumor associated fibroblast and the vasculature is promising, but the heterogeneity of tumors entails a thorough validation of suitable markers for targeted delivery. Thus, we elucidated the potential of bispecific liposomes targeting the fibroblast activation protein (FAP) on tumor stromal fibroblasts, together with endoglin which is overexpressed on tumor neovascular cells and some neoplastic cells. Fluorescence-quenched liposomes were prepared by hydrating a lipid film with a high concentration of the self-quenching near-infrared fluorescent dye, DY-676-COOH, to enable fluorescence detection exclusively upon liposomal degradation and subsequent activation. A non-quenched green fluorescent phospholipid was embedded in the liposomal surface to fluorescence-track intact liposomes. FAP- and murine endoglin-specific single chain antibody fragments were coupled to the liposomal surface, and the liposomal potentials validated in tumor cells and mice models. The bispecific liposomes revealed strong fluorescence quenching, activatability, and selectivity for target cells and delivered the encapsulated dye selectively into tumor vessels and tumor associated fibroblasts in xenografted mice models and enabled their fluorescence imaging. Furthermore, detection of swollen lymph nodes during intra-operative simulations was possible. Thus, the bispecific liposomes have potentials for targeted delivery into the tumor microenvironment and for image-guided surgery.
7
Fathalla, Dina, Eman M. K. Youssef y Ghareb M. Soliman. "Liposomal and Ethosomal Gels for the Topical Delivery of Anthralin: Preparation, Comparative Evaluation and Clinical Assessment in Psoriatic Patients". Pharmaceutics 12, n.º 5 (11 de mayo de 2020): 446. http://dx.doi.org/10.3390/pharmaceutics12050446.
Texto completoResumen
To enhance anthralin efficacy against psoriasis and reduce its notorious side effects, it was loaded into various liposomal and ethosomal preparations. The nanocarriers were characterized for drug encapsulation efficiency, size, morphology and compatibility between various components. Optimum formulations were dispersed in various gel bases and drug release kinetics were studied. Clinical efficacy and safety of liposomal and ethosomal Pluronic®F-127 gels were evaluated in patients having psoriasis (clinicaltrials.gov identifier is NCT03348462). Safety was assessed by recording various adverse events. Drug encapsulation efficiency ≥97.2% and ≥77% were obtained for liposomes and ethosomes, respectively. Particle sizes of 116 to 199 nm and 146 to 381 nm were observed for liposomes and ethosomes, respectively. Fourier-Transform infrared (FT-IR) spectroscopy and differential scanning calorimetry (DSC) studies confirmed the absence of interaction between anthralin and various nanocarrier components. Tested gel bases showed excellent ability to sustain drug release. At baseline, the patients had a median Psoriasis Area and Severity Index (PASI) of 3.4 for liposomes and 3.6 for ethosomes without significant difference. After treatment, mean PASI change was −68.66% and −81.84% for liposomes and ethosomes, respectively with a significant difference in favor of ethosomes. No adverse effects were detected in both groups. Anthralin ethosomes could be considered as a potential treatment of psoriasis.
8
Al-Mahmood, Sumayah. "Targeting Breast Cancer Stem Cells (BCSCs) with Liposomal Formulations". Clinical Cancer Drugs 6, n.º 1 (27 de septiembre de 2019): 3–7. http://dx.doi.org/10.2174/2212697x06666190318150757.
Texto completoResumen
Breast cancer stem cells (BCSCs) are a small proportion of cells that may be responsible for improving the resistance of cancer cells to the treatment and metastasis of breast cancer (MBC). Nanovehicles such as liposomes are extensively explored for diagnosis, treatment, and imaging of cancer. Targeted therapy with nanoparticles can be used to overcome the chemoresistance problem of cancer stem cells. Liposomes are lipid bilayer nanocarriers that have the ability to inhibit Pglycoprotein to overcome multidrug resistance that makes liposome ideal choice for using in BCSCs therapy. The main objective of this review is to describe novel liposomal formulations that are used in targeting BCSCs, which help in improving breast cancer treatment.
9
Perminaite, Kristina, Anna Maria Fadda, Chiara Sinico y Kristina Ramanauskiene. "Formulation of Liposomes Containing Royal Jelly and Their Quality Assessment". Journal of Nanoscience and Nanotechnology 21, n.º 5 (1 de mayo de 2021): 2841–46. http://dx.doi.org/10.1166/jnn.2021.19053.
Texto completoResumen
Royal jelly, a gelatinuous consistency bee product produced and secreted by the hypopharyngeal and mandibular glands of worker honeybees, is beneficial in the treatment of dermatological conditions, likely through its content of the fatty acid 10-hydroxy-2-decenoic acid (10-HDA). However, 10-HAD poorly penetrates into skin. Thus, in this work, we produced royal jelly incorporated liposomes with the aim of increasing skin penetration of 10-HDA. Lipid nanocarriers were prepared by the thin lipid-film hydration method. Size and polydispersity index of the nanocarrier particles, and their stability over 30 days were measured. The effects of royal jelly and 10-HDA liposomal formulations on the viability of immortalized human keratinocyte cells were tested with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The skin penetration of 10-HDA from liposomal formulations and royal jelly solution was studied in vitro with Franz type vertical diffusion cells using porcine skin as limiting membrane. As result, small liposomes were achieved, and the efficacy of the obtained nanoformulations was examined by means of in vitro cell assays with a HaCaT immortalized human keratinocyte cell culture line. Finally, the skin penetration experiments showed that liposomal incorporation greatly increased 10-HDA penetration into skin layers.
10
Pandya, Tosha, Kaushika Kaushika Patel, Rudree Pathak y Shreeraj Shah. "Liposomal Formulations In Cancer Therapy: Passive Versus Active Targeting". Asian Journal of Pharmaceutical Research and Development 7, n.º 2 (14 de abril de 2019): 35–38. http://dx.doi.org/10.22270/ajprd.v7i2.489.
Texto completoResumen
In Cancer therapy, Nano drug delivery system comprising of Liposomes, are the most successful mode of treatment in present scenario which also has real time clinical application. Recently it is found that the closed bilayer phospholipid vesicles have many technical advantages over the initially used liposomal formulations. The delivery of therapeutics encapsulated in liposomes changes the biological distribution profile and improves the drug therapeutic indices of various drugs. This review article throws light onto many clinical liposomal drug delivery products. The liposome Nano drug delivery by the active and passive targeting is a boon as it can reduce the off-targeting effects. The current development is more focused on the diagnostic and clinical applications. Receptor targeted delivery systems are extensively explored for active targeting. However, these delivery systems are rarely seen in the clinical application because of conjugation chemistry and other implicit hurdles to develop this system.The development of nanocarriers in the cancer treatment have enormous potential in the medical field. Moreover, Immuno liposomes have been used in cancer treatment as attractive drug targeting vehicles. On the other hand, there are many other liposomal drug delivery systems having passive targeting mechanism for cancer treatment which are widely used due to enhanced retention and permeability of formulation. This review majorly focuses on the current challenges encountered in development of liposomal Nano drug delivery systems and its effective development for cancer treatment.
Tesis sobre el tema "Nanocarrier Liposoma"
1
Munson, Jennifer Megan. "Novel nanocarriers for invasive glioma". Diss., Georgia Institute of Technology, 2011. http://hdl.handle.net/1853/41226.
Texto completoResumen
The invasive nature of glioblastoma (GBM) represents a significant challenge to the standard of care and contributes to poor clinical outcomes. Invasion of tumors into healthy brain restricts chemotherapeutic access and complicates surgical resection. The central hypothesis of the thesis is that an effective anti-invasive agent can enhance the standard chemotherapeutic response in invasive brain tumors. Through a screen of novel compounds, a new anti-invasive small molecule, Imipramine Blue (IB), was identified. This triphenylmethane compound inhibits invasion of highly invasive glioma in vitro and in vivo. To elicit a response in vivo, Imipramine Blue was liposomally encapsulated to yield better delivery to tumor. Using this formulation, it is shown that IB attenuates invasion of glioma in vivo leading to a more compact tumor in an aggressively invasive rodent glioma model. Further, it is shown that this novel compound binds NADPH oxidases and alters expression of actin regulatory elements to elicit this anti-invasive activity. To test our hypothesis that anti-invasive therapy coupled with chemotherapy will enhance efficacy, nano-IB therapy was followed by liposomally encapsulated doxorubicin (DXR) chemotherapy. Additionally, a co-encapsulated formulation of IB and DXR was developed and tested in vivo. This combination therapy significantly enhanced survival compared to IB or DXR alone, resulting in long-term survival in the syngeneic invasive rat astrocytoma model RT2. It was seen that sequential treatment was more effective than the co-encapsulated treatment indicating a benefit of pre-treating the tumor with the anti-invasive. This thesis demonstrates that novel anti-invasive IB mediated 'containment' of diffuse glioma significantly enhances the efficacy of DXR chemotherapy compared to chemotherapy or anti-invasive therapy alone.
2
Kolter, Melanie [Verfasser] y Regine [Akademischer Betreuer] Süss. "Liposomal nanocarriers for curcumin delivery and evaluation of endocytic inhibitors". Freiburg : Universität, 2018. http://d-nb.info/116018643X/34.
Texto completo
3
Barattin, Michela. "Development of nanocarriers with responsive interfacial properties for site-specific drug delivery". Doctoral thesis, Università degli studi di Padova, 2016. http://hdl.handle.net/11577/3424682.
Texto completoResumen
The functional and morphological alterations of the vascular endothelium of the lymphatic system, the micro-environmental alterations such as the amplification of the enzyme kit, the overexpression of specific receptors, the increase in the redox potential, temperature and the lowering of the pH, are typical characteristics of tumor tissues. These features can be exploited successfully for the development of suitable supramolecular and colloidal systems with passivelly and activelly guided delivery of anticancer drugs at the site of action. Here we aimed at investigating a novel pH responsive liposomal platform to achive selective tumor targeting to ensure the accumulation of the drug in adequate therapeutic concentration. Liposomes were decorated with a novel non-peptidic cell penetrating enhancer (CPE) that simulates the action of the natural peptides known from the literature studies. A synthetic procedure was developed to obtain a oligoarginyl-dendron derivative to be included in the lipid bilayer of the liposomes. The derivative TetraBoc-Arg(pbf)-[G-2]-distearoyl glycerol (Arg4-DAG) consists of a central polyester core to which arginines were conjugated on one side and that was terminated with a distearoyl glycerol chain on the other. The resulting macromolecule possesses a amphiphilic character in virtue of its two combined moieties: 1) the hydrophobic distearoyl tail acting as lipidic anchor for lipid bilayer association , 2) the positively charged peripheral arginines, which provides for high cationic density and mimic the basic aminoacid residues of TAT peptide, thus conferring the biological activity to the system. The intermediates and the final product were characterized by 1H, 13C NMR and mass spectrometries.
Liposomes obtained with a 2:1 HSPC/cholesterol molar ratio were generated with increasing ratio of the CPE with respect to lipids using the post insertion technique which provided for the increase of liposome zeta potential from +8 mV to +24 mV as the ratio of CPE increased from 1% to 4%, then reaching a plateau.
The biological properties of fluorescently labelled CPE coated liposomes were investigated on HeLa cancer cells. Flow cytometry analysis and confocal microscopy study confirmed the high capacity of the liposomes to associate with cells. A 30 times higher efficiency of cancer cell association was found with respect to naked liposomes. The CPE coated liposomes demonstrated a remarkable ability to deliver in the cytosol albumin and calcein. BSA was chosen as protein model, whereas calcein was selected because it is a strongly hydrophilic molecule, so as to mimic the behavior of water soluble drugs. Both molecules were incorporated into the hydrophilic core of liposomes. The calcein was not release from the liposomes for at least 16 days, whereas BSA was completely released in 7 days.
In order to confer to liposomes sensitivity to pH alterations for controlled access to cancer cells, a pH sensitive polymer of mPEG-oligosulphadimethoxine (mPEG5kDa-SDM8) was synthesized by radical polymerization of sulfadimethoxine methacrylate from 2-bromo-isobutyryl-methoxyPEG (mPEG-Br) 5kDa. mPEG5kDa-SDM8 possesses a pKa of 7.12 which ensures a deprotonated state with negative charge at physiological pH (7.4) and a protonated neutral state at pH 6.5, which corresponds to the tumor environment.
Zeta potential analysis performed on Arg4-DAG coated liposomes decorated with the mPEG5kDa-SDM8 polymer confirmed that the most finely regulated shielding/unshielding capacity is obtained when the two modules are equimolar, both at 4% in moles with respect to lipids. This formulation was found to be stable even in the presence of serum proteins, which does not alter the charge-to-charge interaction between the oligo-sulfadimethoxine of the pH responsive polymer and oligo-arginines of the CPE as observed by zeta potential analysis. The SPR study also confirmed this result, proving the polymer association with the CPE coated liposomes at pH 7.4 and the release at pH 6.5 mimicking the tumor, which corresponds to a sheddable physical PEGylating under controllable conditions.
Finally, the biological studies confirmed the ability of the pH responsive polymer to shield the CPE on the liposomal surface under physiological conditions (pH 7.4), which prevents the internalization of both the unloaded pH responsive vesicles, and the calcein loaded vesicles, whereas revealing it when exposed to tumor mimicking acid environment, allowing for liposome cell entry and payload intracellular delivery.Alterazioni funzionali e morfologiche dell'endotelio vascolare del sistema linfatico, alterazioni micro-ambientali quali l'amplificazione del kit enzimatico, sovraespressione di recettori specifici, aumento del potenziale redox, temperatura e abbassamento del pH, sono caratteristiche tipiche dei tessuti tumorali. Queste caratteristiche possono essere sfruttate con successo per lo sviluppo di sistemi colloidali sopramolecolari in grado di direzionare passivamente o attivamente farmaci antitumorali al sito d'azione. In questo lavoro è stata indagata una nuova piattaforma liposomiale sensibile al pH per il direzionamento selettivo al tumore e assicurare l'accumulo del farmaco in concentrazione terapeutica adeguata. I liposomi sono stati decorati con un nuovo promotore di internalizzazione cellulare non-peptidico che simula l'azione dei peptidi naturali conosciuti dagli studi di letteratura. È stata messa a punto una nuova procedura di sintesi per ottenere il derivato dendronico oligoargininico da includere nel doppio strato lipidico dei liposomi. Il derivato TetraBoc-Arg (PBF) - [G-2] -distearoil glicerolo (Arg4-DAG) è costituito da un nucleo centrale di poliestere a cui le arginine sono state coniugate su un lato e che è stato terminato con una catena distearoil glicerolo dall'altro. La macromolecola risultante possiede un carattere anfifilico in virtù delle sue due frazioni combinate: 1) la coda idrofoba distearoil, elemento lipidico di ancoraggio per associazione al doppio strato lipidico, 2) la carica positiva conferita dalle arginine periferiche, che mimano i residui amminoacidici fondamentali del peptide TAT, conferendo così l'attività biologica del sistema. Gli intermedi e il prodotto finale sono stati caratterizzati da 1H, 13C NMR e spettrometria di massa. I liposomi ottenuti con un rapporto molare 2:1 HSPC/colesterolo sono stati generati con crescente rapporto del CPE rispetto ai lipidi, utilizzando la tecnica di ‘post-insertion’, che ha determinato l'aumento del potenziale zeta dei liposomi da +8 mV a +24 mV, all’aumentare del rapporto di CPE dall'1% al 4%, raggiungendo quindi il plateau. Le proprietà biologiche dei liposomi rivestiti con il CPE fluorescente sono state studiate su cellule tumorali HeLa. L’analisi citofluorimetrica e lo studio di microscopia confocale hanno confermato l'elevata capacità dei liposomi di associare con le cellule. Rispetto al liposomi nudi, è stata rilevata una maggiore efficienza di associazione alla cellula tumorale di 30 volte. I liposomi rivestiti col CPE hanno dimostrato una notevole capacità di veicolare albumina e calceina nel citosol. BSA è stata scelta come proteina modello, mentre calceina è stata scelta perché è una molecola fortemente idrofila, in modo da simulare il comportamento di farmaci idrosolubili. Entrambe le molecole sono state incorporate nel nucleo idrofilo di liposomi. La calceina non è stata rilasciata dai liposomi per almeno 16 giorni, mentre BSA è stata completamente rilasciata in 7 giorni. Al fine di conferire ai liposomi responsività ad alterazioni di pH per l'accesso controllato alle cellule tumorali, è stato sintetizzato un polimero sensibile, pH mPEG-oligosulphadimethoxine (mPEG5kDa-SDM8), mediante polimerizzazione radicalica di sulfadimetossina metacrilato su una catena di 2-bromo-isobutirril-methoxyPEG (MPEG-Br ) 5kDa. mPEG5kDa-SDM8 possiede un pKa di 7,12 che garantisce uno stato deprotonato con carica negativa a pH fisiologico (7.4) e uno stato neutro protonato a pH 6,5, che corrisponde all'ambiente tumorale. L’analisi di potenziale Zeta eseguita su liposomi decorati con Arg4-DAG e con il polimero mPEG5kDa-SDM8 ha confermato che la capacità di schermatura/deschermatura più finemente regolata si ottiene quando i due moduli sono equimolari, entrambi a 4% in moli rispetto al lipidi. Questa formulazione è risultata stabile anche in presenza di proteine del siero, che non alterano l'interazione carica-carica tra l'oligo-sulfadimetossina del pH del polimero reattivo e oligo-arginine del CPE come osservato mediante analisi potenziale zeta. Anche lo studio SPR ha confermato questo risultato, dimostrando l'associazione del polimero con i liposomi rivestiti col CPE a pH 7.4 e il rilascio a pH 6,5, che corrisponde ad una peghilazione fisica reversibile in condizioni controllabili. Infine, gli studi biologici hanno confermato la capacità del polimero pH sensibile di schermare il CPE sulla superficie liposomiale in condizioni fisiologiche (pH 7,4), che impedisce l'internalizzazione delle vescicole non responsive al pH sia non caricate, sia caricate con calceina, mentre il polimero espone il CPE sulla superficie dei liposomi in presenza di un ambiente acido che simula il tumore, consentendo l'ingresso ai liposomi nelle cellule e la veicolazione del loro contenuto a livello intracellulare.
4
Agarwal, Abhiruchi. "Nanocarrier mediated therapies for the gliomas of the brain". Diss., Georgia Institute of Technology, 2011. http://hdl.handle.net/1853/39468.
Texto completoResumen
Existing methods of treating glioma are not effective for eradicating the disease. Therefore, new and innovative methods of treatment alone or in combination with existing therapies are necessary. Delivery of therapeutic agents through delivery carriers such as liposomes diminishes the harmful effects of the agent in healthy tissues and allows increased accumulation in the tumor. In addition, targeted chemotherapy using liposomes provides the opportunity for further increase in drug accumulation in tumor. However, the current targeting strategies suffer accelerated plasma clearance and are not advantageous in improving efficacy. The search for new tumor targets, novel ligands, new strategies for targeting, and particle stabilization will advance our ability to improve delivery at the tumor level while decreasing toxicity to normal tissues.
The global objective of this thesis was to improve the status of current liposomal therapy to achieve higher efficacy in tumors. Here, we show a novel mechanism to increase targeting to tumor while uncompromising on the long circulation of stealth liposomes. Long circulation is essential for passive accumulation of the nanocarriers due to EPR effect, in order to see benefits of targeting. Using phage display technique, a variety of tumor specific peptides were identified for use as targeting moieties. One potential advantage of the approach proposed here is the rapid identification of patient tumor specific peptide that evades the RES. This could lead to the development of a nanocarrier system with high avidity and selectivity for tumors. Therefore, tumor accumulation of the targeted formulations will be higher than that of non‐targeted liposomes due to increased drug retention at the tumor site and uncompromised blood residence time.In addition, it has been shown that the distribution of nanocarriers, spatially within the tumor, is limited that might further hinder the distribution of the encapsulated drug, thereby limiting efficacy. It is necessary to release the drug from within the nanocarrier to promote increased efficacy. Here, we were able to address the problem of drug diffusion within the tumor interstitium using a combination therapy employing a remotely triggered thermosensitive liposomal chemotherapeutic. We fabricated a thermosensitive liposomal nanocarrier that maintained its stability at physiological temperature to minimize toxicity to healthy cells. We, then, showed a remote triggering mechanism mediated by gold nanorods heated via NIR can help in achieving precise control over the desired site for drug release. These strategies enabled increased drug availability at the tumor site and contributed to tumor retardation. Additionally, we show that the synergistic therapy employing gold nanorods and thermosensitive liposomes may have great potential to be translated to the clinic.
5
Cureton, Natalie. "Development of nanocarriers for targeted drug delivery to the placenta". Thesis, University of Manchester, 2017. https://www.research.manchester.ac.uk/portal/en/theses/development-of-nanocarriers-for-targeted-drug-delivery-to-the-placenta(696cfc4f-0bd7-4fbe-9b23-d2b83a7fec7d).html.
Texto completoResumen
Pregnancy complications such as fetal growth restriction (FGR) are often attributed to poor uteroplacental blood flow, but the risk of systemic side-effects hinders therapeutic intervention. We have utilised novel placental-specific homing peptides to overcome this and have conjugated these to biocompatible liposomes. Peptide-conjugated liposomes were found to selectively bind to the outer syncytiotrophoblast layer of the human placenta and to the uteroplacental vasculature and labyrinth region of the mouse placenta. The novel vasodilator SE175 was selected as a nitric oxide donor with a favourable stability and release profile, to encapsulate in peptide-conjugated liposomes in an attempt to restore impaired uteroplacental blood flow in a mouse model of FGR, the endothelial nitric oxide synthase knockout mouse. Liposomes containing SE175 or PBS were prepared by lipid film hydration and targeting peptides coupled to the liposomal surface. Vehicle control, free SE175, PBS- or SE175-containing liposomes were intravenously injected on embryonic (E) days 11.5, 13.5, 15.5 and 17.5. Animals were sacrificed at E18.5 and fetal and placental weights recorded. Targeted delivery of SE175 significantly increased fetal weight compared to vehicle control but no other treatment groups, whilst significantly decreasing placental weight, indicating improved placental efficiency. Treatment was well tolerated, having no impact on litter size or resorptions. Targeted delivery of SE175, but no other treatment group, reduced a marker of lipid peroxidation in the placenta, indicating a reduction in oxidative stress. These data suggest that selective delivery of SE175 to the uteroplacental vasculature in peptide decorated liposomes may represent a novel treatment for FGR.
6
Karim, Reatul. "Design of Nanocarriers to Deliver Small Hydrophobic Molecules for Glioblastoma Treatment". Thesis, Angers, 2017. http://www.theses.fr/2017ANGE0055/document.
Texto completoResumen
Le but de cette thèse de doctorat fut de développer des nanoparticules pour la délivrance de deux molécules hydrophobes de faible poids moléculaire, l’apigénine (AG) et un ferrocifène (FcTriOH), comme stratégie innovante pour le traitement du glioblastome(GBM). Dans un premier temps, différents types de nanoparticules, liposomes, nanocapsules lipidiques (LNC), et nanocapsules à base de polymères, furent formulés et comparés en termes de caractéristiques physico-chimiques, de libération en drogue ou encore de toxicité. Les LNCs furent ainsi sélectionnées. Dans un deuxième temps, les LNCs furent fonctionnalisées en surface par un peptide pénétrant (CPP). La concentration de peptide fut augmenté afin d’améliorer significativement l’internalisation des LNCsdans des cellules humaines de GBM. Les mécanismes de macropinocytose et d’endocytose dépendant de la clathrine et de la cavéoline furent observés. De plus, il fut montré que l’internalisation de ces LNCs fonctionnalisées était réduite dans les cellules saines humaines d’astrocyte. L’efficacité biologique des LNCs chargées en AG et chargées en FcTriOH fut évaluée et comparée : le résultat le plus prometteur fut obtenu avec les LNCs chargées en FcTriOH. Une administration intracérébrale des LNCs sur un modèle tumoral murin orthotopique montra une potentielle toxicité et un besoin d’optimiser la dose administrée. Pour finir, les études menées sur un modèle tumoral ectopique murin montrèrent des résultats prometteurs, après une administration parentérale des LNCs chargées en FcTriOH. Ainsi, cette dernière formulation pourrait ouvrir la voie au développement d’une stratégie thérapeutique alternative pour le traitement du GBMThe aim of this thesis was to develop nanocarriers for efficient delivery of two low molecular weight hydrophobic drugs, apigenin (AG) and a ferrocifen-derivative(FcTriOH) to glioblastoma (GBM) as potential therapeutic strategies. Firstly, two liposomes, a lipid nanocapsule (LNC), and a polymer-based nanocapsule were develope dand compared by their physicochemical characteristics, drug loading capacity, storage stability, stability in biological serum, drug release profiles, complement consumption and toxicity. Due to various advantageous characteristics, the LNCs were selected for further optimization. Secondly, the LNCs were surface functionalized by adsorbing a GBM-targeting cellpenetratingpeptide (CPP). The CPP concentration increased to significantly enhance LNCinternalization in human GBM cells. The uptake mechanisms observed in U87MG cellswere : micropinocytosis, clathrin-dependent and caveolin-dependent endocytosis. Moreover, the optimized CPP-functionalized LNCs were internalized preferentially in theGBM cells compared to normal human astrocytes. Additionally, the in vitro efficacy of the AG-loaded and FcTriOH-loaded LNCs was evaluated. The FcTriOH-loaded LNC-CPP showed the most promising activity with a low IC50 of 0.5 μM against U87MG cells. Intracerebral administration of the LNCs in a murine orthotopic U87MG tumor modelshowed possible toxic effects and the need for dose optimization. Finally, studies inmurine ectopic U87MG tumor model showed promising activity after parenteral administration of the FcTriOH-loaded LNCs. Overall, these results exhibit the promising activity of FcTriOH-loaded LNCs as potential alternative GBM therapy strategy
7
Luna, Arthur Cassio de Lima. "Potencial antitumoral da formulação lipossomal DODAC/fosfoetanolamina sintética no modelo de hepatocarcinoma". Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/5/5167/tde-15122017-092710/.
Texto completoResumen
A fosfoetanolamina sintética (FO-S), um fosfomonoéster, apresenta relevante atividade antitumoral. Contudo, a utilização de um carreador para encapsular a FO-S em lipossomas poderia favorecer a sua disponibilidade no microambiente tumoral, possibilitando o aumento da sua eficácia. Desta forma, o presente estudo avaliou a eficiência de encapsulamento da FO-S em lipossomas de DODAC e o seu potencial antitumoral. Os lipossomas foram preparados por ultrasonicação e caracterizados físicoquimicamente. A citotoxidade foi avaliada nas linhagens tumorais B16F10 (melanoma murino), Hepa1c1c7 (hepatocarcinoma murino) e Skmel-28 (melanoma humano) e nas células normais HUVEC, após o tratamento com diferentes concentrações dos lipossomas DODAC/FO-S, no tempo de 24 horas. A internalização dos lipossomas e o potencial elétrico mitocondrial foram analisados por microscopia confocal a laser. Adicionalmente, a expressão das proteínas caspases 3 e 8 ativas, receptor DR4, citocromo c, p53, p21, Bax, p27, CD44, CD90, Bcl-2 e ciclina D1 foi quantificada por citometria de fluxo. Para os estudos in vivo, os camundongos C57BL/6J portadores de hepatocarcinoma foram tratados com FO-S, DODAC/FO-S e DODAC, pelas vias intraperitoneal (IP) e intrahepática (IH), durante 20 dias. Os resultados demonstraram que os lipossomas apresentaram aspecto esférico e alta eficiência de encapsulação da FO-S, como também promoveram maior citotoxicidade nas linhagens tumorais estudadas, em comparação com FO-S. Além disto, nas células B16F10 e Hepa1c1c7, ocasionou parada nas fases S e G2/M do ciclo celular. A linhagem Hepa1c1c7 foi a mais sensível ao tratamento com os lipossomas DODAC/FO-S, os quais foram internalizados em até 6 horas e promoveram a diminuição de CD90, CD44, ciclina D1 e Bcl-2, o aumento de p53, p21, p27, Bax e caspases 8 e 3 ativas e a liberação do citocromo c. O aumento significativo das caspases 8 e 3 ativas, expressão do receptor DR4 e a liberação do citocromo c também ocorreu nas linhagens B16F10 e Skmel-28. Os resultados in vivo mostraram que os lipossomas DODAC/FO-S e a FO-S não induziram hepatotoxicidade, nefrotoxicidade e caquexia. Os lipossomas DODAC/FO-S não ocasionaram mielossupressão e hemólise, apresentando menor toxicidade em relação a FO-S, administrada pelas vias IP e IH. Além disto, os tratamentos com DODAC/FO-S (IH) e FO-S (IH e IP) foram efetivos em diminuir o número de células na fase S. Contudo, apenas os lipossomas DODAC/FO-S (IH) reduziram significamente os focos tumorais, aumentando as áreas de necrose, promovendo também o aumento da expressão gênica da p53, ciclina B1 e caspases 8 e 3. O conjunto dos resultados in vivo e in vitro demonstraram que a formulação lipossomal DODAC/FO-S foi capaz de maximizar os efeitos antitumorais da FO-S, ativando as vias intrínsecas e extrínsecas da apoptoseSynthetic phosphoethanolamine (PHO-S) - a phosphomonoester - has shown relevant anticancer effects. However, the utilization of a carrier to encapsulate the PHOS in liposomes can maximize its availability in the tumor microenvironment, allowing an increase in its effectiveness. Thus, the present study has evaluated efficiency of PHO-S encapsulation in DODAC liposomes and its antitumor potential. The liposomes were prepared by ultrasonication and physico-chemically characterized. The cytotoxic effects were evaluated on B16F10 cells (murine melanoma), Hepa1c1c7 cells (murine hepatocellular carcinoma), Skmel-28 (human melanoma) and in endothelial cells HUVEC, after treatment with DODAC/PHO-S liposomes at different concentrations for 24 hours. The internalization of the liposomes and mitochondrial electrical potential were analyzed by confocal laser microscopy. Additionally, the expression of active caspases 3 and 8, receptor DR4, cytochrome c, p53 p53, p21, Bax, p27, CD44, CD90, Bcl-2 and cyclin D1 proteins was quantified by flow cytometry. For in vivo studies, C57BL/6J mice with hepatocellular carcinoma were treated with PHO-S, DODAC/PHO-S and DODAC, by intraperitoneal (IP) and intratumoral (IT) routes for 20 days. The results demonstrated that liposomes presented spherical aspect and high PHO-S encapsulation efficiency, as also promoted high cytotoxic effect - compared with PHO-S. Furthermore, in B16F10 and Hepa1c1c7 cells, the liposomes induced S and G2/M cell cycle arrest. Hepa1c1c7 cells showed greater sensitivity to the DODAC/PHO-S formulation, which were internalized until 6 hours and promoted a decrease in the expression of CD90, CD44, cyclin D1 and Bcl-2, an increase of de p53, p21, p27, Bax and active caspases 8 and 3 and the liberation of cytochrome c. The significant increase in the expression of active caspases 3 and 8, DR4 receptor and liberation of cytochrome c also occurred in B16F10 and Skmel-28 cells. In vivo results showed that DODAC/PHO-S liposomes and PHO-S did not induce nephrotoxicity, hepatotoxicity and cachexia. DODAC/PHO-S liposomes did not cause myelosuppression and hemolysis, presenting lower toxicity in relation to PHO-S - when administered by IP and IT routes. Moreover, treatment with DODAC/PHO-S (IT) and PHO-S (IT and IP) effectively decreased the number of cells in S phase. However, only DODAC/PHO-S liposomes significantly reduced the number of tumor foci, increasing area of necrosis, and also promoting an increase in gene expression of p53, cyclin B1 and caspases 8 and 3. The set of in vitro and in vivo results demonstrated that DODAC/PHO-S liposomal formulation was capable of maximizing the PHO-S antitumor effects, activating the intrinsic and extrinsic pathways of the apoptosis
8
Borin, Diego Becker. "PRODUÇÃO DE LIPOSSOMAS DE CREATINA, AVALIAÇÃO DA TOXICIDADE E DE EFEITO NEUROPROTETOR EM MODELO ANIMAL DE NEURODEGENERAÇÃO". Centro Universitário Franciscano, 2017. http://www.tede.universidadefranciscana.edu.br:8080/handle/UFN-BDTD/574.
Texto completoResumen
Submitted by MARCIA ROVADOSCHI (marciar@unifra.br) on 2018-08-20T12:27:29Z
No. of bitstreams: 2
license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Tese_DiegoBeckerBorin.pdf: 7060697 bytes, checksum: bbf39761011feb8708ec27ab4968daed (MD5)Made available in DSpace on 2018-08-20T12:27:29Z (GMT). No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Tese_DiegoBeckerBorin.pdf: 7060697 bytes, checksum: bbf39761011feb8708ec27ab4968daed (MD5) Previous issue date: 2017-03-27
The pathophysiology of neurodegenerative diseases is associated with neuronal loss or dysfunction, whose characteristics are determined due to cerebral area affected and progression of the disease. Creatine has physiological importance as energy buffer and storage having protective effects in animal models of neurodegenerative diseases. However, its permeability through the blood-brain barrier (BBB) is very low. The objective of this study is was developing a nanoliposome carrier to facilitate the delivery of creatine to the central nervous system (CNS), thus could potentiate the effects of creatine. In order to test the safety of liposomes toxicity, assays were performed in cell culture and in vivo, as well as analyzed in streptozotocin-induced (STZ) dementia model. The method of production of liposomes by ethanol injection, proved to be efficient, since particles with a polydispersion index (PDI) of 0,237, negative Zeta potential (-12.5 mV) and average size of 213 nm were obtained. The size was confirmed by transmission electron microscopy where spherical particles of 100-200 nm were observed. In in vitro toxicity assays, blank liposomes (without creatine - BL) as well as creatine liposomes (CrL) at concentrations of 0.02 and 0.2 mg/mL did not alter the viability of VERO cells cultured. It also did not alter viability of neural cells in hippocampal slices from adult rats. In toxicity assays in vivo, subchronic treatment with both liposomes did no changes hematological and biochemical markers in blood of young rats, but an increased in creatine concentrations were observed in the brains of CrL-treated animals was observed. In the animal model of STZ-induced dementia in adult mice, behavioral changes such as habituation memory deficit and long-term aversive memory were reversed by 21 days treatment with free creatine and CrL. The animals of the STZ groups did not present alterations in energetic metabolism enzymes in the hippocampus, but they showed a reduction in creatine levels in cerebral tissue, which was reversed by the treatment with free creatine and CrL. It is suggested from the results that CrL can be used safely, but further studies should be performed to verify its performance in other neurodegeneration models.
A fisiopatologia de doenças neurodegenerativas está associada à perda ou disfunção neuronal, cujas características são determinadas pela região onde ocorre a perda e pela velocidade de progressão da doença. A creatina possui importância fisiológica como mecanismo de reserva e tampão energético tendo efeitos protetores em modelos animais de doenças neurodegenerativas, apesar de possuir baixa permeabilidade através da barreira hematoencefálica (BHE). Assim, o objetivo do presente estudo foi desenvolver um carreador lipossomado para facilitar a entrega de creatina ao sistema nervoso central (SNC), e assim potencializar os efeitos da creatina livre. Com a finalidade de testar a segurança dos lipossomas testes de toxicidade em cultura de células e in vivo foram realizados, assim como testes em um modelo de demência induzido por estreptozotocina (STZ) para avaliar sua funcionalidade, também foi avaliada a concentração de creatina no SNC dos animais. O método de produção de lipossomas por meio da injeção de etanol demonstrou ser eficiente, pois foram obtidas partículas com índice de polidispersão (IPD) 0,237, potencial Zeta de -12,5 mV e tamanho médio de 213 nm. O tamanho foi confirmado por microscopia eletrônica de transmissão onde observou-se partículas esféricas de 100 a 200 nm. Nos testes de toxicidade in vitro, os lipossomas brancos (sem creatina - LB) bem como os lipossomas de creatina (LCr) nas concentrações de 0,02 e 0,2 mg/mL não alteraram a viabilidade de células em cultura da linhagem VERO, e tampouco de fatias da área cerebral hipocampo de ratos adultos. Nos testes de toxicidade in vivo, não foram observadas alterações com o tratamento subcrônico com ambos lipossomas em marcadores hematológicos e bioquímicos em ratos filhotes, porém foi observado um aumento nas concentrações de creatina no cérebro dos animais tratados com LCr. No modelo animal de demência induzido por STZ em camundongos adultos foram observadas alterações comportamentais como déficit de memória de habituação e aversiva de longo prazo ambas revertidas pelo tratamento de 21 dias com creatina livre e LCr. Os animais dos grupos STZ não apresentaram alterações em enzimas do metabolismo energético no hipocampo, porém apresentaram redução nos níveis de creatina, que foi revertido pelo tratamento com creatina livre e LCr. Sugere-se a partir dos resultados obtidos, que os LCr podem ser utilizados com segurança, porém mais estudos devem ser realizados para verificar seu desempenho em outros modelos de neurodegeneração.
9
Rodríguez, Amigo Beatriz. "Light-sensitive nanocarriers for drug delivery in photodynamic therapy". Doctoral thesis, Universitat Ramon Llull, 2018. http://hdl.handle.net/10803/462210.
Texto completoResumen
Aquesta tesi aprofundeix en l’estudi de nanotransportadors com a sistemes de vehiculització i en alguns casos, alliberació de fotosensibilitzadors emprats en teràpia fotodinàmica. S’han fet servir dos nanotransportadors de naturalesa diferent: proteïnes i liposomes.
En primer lloc s’ha investigat els complexos formats entre la hipericina i les proteïnes apomioglobina i β-lactoglobulina. S’han estudiat les característiques fisicoquímiques i fotofísiques, avaluant l’activitat antimicrobiana en front a bacteris gram-positius i gram-negatius. En ambdues matrius proteiques el fotosensibilitzador es troba majoritàriament en forma monomèrica, preservant les seves propietats fotofísiques i formant un complex estable. En el cas de la β-lactoglobulina s’estudia a més, la formació del complex amb l’adició d’un 20% de DMSO com a co-solvent, fet que millora les propietats fotofísiques en detriment de la capacitat antimicrobiana. Ambdós complexos proteics son efectius contra bacteris gram-positius però no contra gram-negatius. Per altra banda, es demostra que la hipericina incorporada a la cavitat de l’apomioglobina pot ser utilitzada en microscòpia de super-resolució STED. Amb aquesta tècnica es pot monitoritzar els llocs d’unió del fotosensibilitzador a la membrana dels bacteris. Així mateix, s’estudia l’ús de la β-lactoglobulina com a portador dual d’hipericina i àcid retinoic. En aquest últim sistema multi-component s’avaluen les propietats fotofísiques per a verificar la formació i estabilitat del complex.
En segon lloc, es desenvolupa un nanovehicle per la seva aplicació en teràpia combinada en el qual s’incorporen fàrmacs quimioterapèutics convencionals amb agents fotosensibilitzants, per superar resistències i millorar l’eficàcia dels tractaments individuals. Amb aquest objectiu, s’han dissenyat i estudiat dues formulacions liposomals diferents, ambdues amb el mateix fotosensibilitzador però encapsulant diferents agents quimioterapèutics. Es preparen formulacions bimodals on s’incorporen els dos agents al mateix vehicle i els seus homòlegs unimodals, amb la incorporació única d’un dels dos agents. S’han avaluat les característiques fisicoquímiques, fotofísiques i fotobiològiques de les suspensions bimodals i unimodals. La lozalització subcel·lular demostra que cada principi actiu es localitza a orgànuls diferents desencadenant rutes de senyalització cel·lular diferents, eludint els possibles mecanismes de resistència. El tractament in vitro en cèl·lules cancerígenes amb aquests sistemes tenen un efecte prometedor, ja que com a mínim presenten un comportament additiu respecte els tractaments individuals. Finalment, s’ha avaluat el potencial de la vehiculització activa mitjançant la unió covalent d’un anticòs monoclonal a la superfície, el que millora lleugerament els resultats per una de les dues formulacions.Esta tesis profundiza en el estudio de nanotransportadores como sistema de vehiculización y en algunos casos, liberación de fotosensibilizadores empleados en terapia fotodinámica. Se emplean dos nanotransportadores de naturaleza distinta: proteínas y liposomas. En primer lugar se han investigado los complejos formados entre hipericina y las proteínas apomioglobina y β-lactoglobulina. Se han estudiado las características fisicoquímicas y fotofísicas, evaluando la actividad antimicrobiana frente bacterias gram-positivas y gram-negativas. En ambas matrices proteicas el fotosensibilizador se encuentra mayoritariamente en forma monomérica, preservando sus propiedades fotofísicas y formando un complejo estable. En el caso de la β-lactoglobulina se estudia además, la formación del complejo con la adición del 20% de DMSO como co-solvente, lo que mejora las propiedades físicas pero sorprendentemente, empeora la capacidad antimicrobiana. Ambos complejos proteicos son efectivos contra bacterias gram-positivas, pero no contra gram-negativas. Además, se demuestra que la hipericina en la cavidad de la apomioglobina es capaz de realizar microscopía de super-resolución STED, mediante la cual se puede monitorizar los sitios de unión a las bacterias. Asimismo, se ha estudiado la β-lactoglobulina como portador dual de hipericina y ácido retinoico. En este último sistema multi-componente se evalúan las propiedades fotofísicas para verificar la formación y estabilidad del complejo. En segundo lugar, se desarrolla un nanovehículo para su uso en terapia combinada en el que se incorpora fármacos quimioterapéuticos convencionales con agentes fotosensibilizantes, para superar las resistencias y mejorar la eficacia de los tratamientos individuales. Con este objetivo, se han diseñado y estudiado dos formulaciones liposomales diferentes, ambas con el mismo fotosensibilizador, pero con diferentes agentes quimioterapéuticos. Se preparan las formulaciones bimodales con ambos agentes en el mismo vehículo además de sus homólogos unimodales, con la incorporación única de uno de los dos agentes. Se han evaluado las características fisicoquímicas, fotofísicas y fotobiológicas de las suspensiones bimodales y unimodales. La localización subcelular demuestra que cada principio activo se localiza en orgánulos diferentes desencadenando rutas de señalización celular diferentes, eludiendo los posibles mecanismos de resistencia. El tratamiento in vitro en células cancerígenas de estos sistemas tiene un efecto prometedor siendo al menos aditivo en comparación con los tratamientos individuales. Finalmente, se ha evaluado el potencial de la vehiculización activa mediante la unión covalente de un anticuerpo monoclonal en la superficie, lo que lleva a resultados ligeramente superiores para una de las dos formulaciones.
This thesis reports the study of nanocarriers as drug delivery systems for photosensitisers in photodynamic therapy. Proteins and liposomes are the two nanovehicles of different nature used for this purpose. Beginning with the proteins, the complexes formed between hypericin and the proteins apomyoglobin and β-lactoglobulin have been explored. The physicochemical and photophysical properties have been studied, as also assessing their photoantibacterial activity against Gram-positive and Gram-negative bacteria. In both protein scaffolds the photosensitiser is found mainly in monomeric form, preserving its fluorescence and singlet oxygen photosensitising properties and yielding a stable complex. In the case of β-lactoglobulin, the complex formation has also been tested with the addition of a 20% DMSO as a co-solvent, which improves the photophysical properties but surprisingly, worsens its antimicrobial activity. Both protein complexes are effective against Gram-positive but not against Gram-negative bacteria. Moreover, it has been proved that hypericin, inside the apomyoglobin cavity, can perform STED microscopy through which its localization in bacteria can be monitored. Additionally, the suitability of β-lactoglobulin as a dual carrier for hypericin and acid retinoic has also been exploited. In this last multi-component system, the photophysical properties have been evaluated to confirm the formation and complex stability. Secondly, a nanocarrier for its use in combined therapy has been developed, in which conventional chemotherapeutic drugs are combined with photosensitising agents to overcome resistance and improve the effectiveness of the individual treatments. For this purpose, two different liposome formulations have been designed and studied with a common photosensitiser but different anti tumour drugs. The bimodal formulations with both agents entrapped and their unimodal counterparts, having each drug loaded in separate liposomes, have been evaluated. The physicochemical, photophysical and photobiological properties of bimodal and unimodal suspensions have been studied. The subcellular localization shows different organelle accumulation by each agent, triggering different key signals transduction pathways, eluding the cellular resistance mechanisms. The treatment in vitro of these multi-component liposomes with cancer cells has a promising effect, since at least an additive outcome is observed when compared with the individual treatments. Finally, we have explored the potential of active targeting strategies by covalently linking a monoclonal antibody to the surface, leading to slightly greater outcomes for one of the liposomal formulations.
10
Dattani, Poonam. "Development and Characterization of LDV Peptide Targeted Nanocarriers for Paclitaxel Delivery: A Comparative Study of Micelles, Liposomes and Solid Lipid Nanoparticles". Scholarly Commons, 2019. https://scholarlycommons.pacific.edu/uop_etds/3623.
Texto completoResumen
Nanocarriers have been established as delivery vehicles to target cancer tumors. However, premature drug leakage is one of the major reasons for inefficient drug delivery of nanocarriers to the tumor. Drug diffusion out of the nanocarriers or destabilization of drug loaded nanocarriers by physiological interactions with blood cells, serum proteins, and cell membranes upon systemic administration contribute to premature drug release. In this study, targeted micelles, liposomes and solid lipid nanoparticles (SLNs) of similar composition were prepared and characterized to compare physicochemical characteristics, in vitro stability, in vitro release rates in release media and in vivo performance. Peptide Amphiphiles (PAs) formed micelles with critical micelle concentration (CMC) values ranging between 23.68 ± 0.72 µM to 38.76 ± 2.27 µM. Transmission Electron Microscopy (TEM) images confirmed the self-assembly of PAs into spherical structures where the largest sizes were seen for C16-(PEG2)6-LDV micelles. Dynamic Light Scattering (DLS) results confirmed the presence of targeted liposomes and SLNs with sizes smaller than 100 nm. Forster Resonance Energy Transfer (FRET) studies revealed that targeted micelles, liposomes and SLNs were all stable upon dilution in aqueous medium, however the stability was significantly reduced in human serum, with micelles being the least stable and SLNs being the most stable. The same trend was observed for the in vitro release profiles, where targeted paclitaxel-loaded micelles (PTX-micelles) had the fastest release rate and paclitaxel-loaded SLNs (PTX-SLN) exhibited the slowest release rate. DLS results showed that sizes of PTX-SLNs were smaller than PTX-liposomes (80.53 ± 5.37 nm vs 123.31 ± 5.87 nm). Cryogenic TEM observation showed increasing size in the order of PTX-micelles (6 to 12 nm) < PTX-SLNs (10-120 nm) < PTX-liposomes (48-145 nm). Drug Loading Content (DLC) of PTX-SLNs was greater than PTX-micelles and PTX-liposomes (7.45 ± 0.41 % vs 1.70 ± 0.42 % and 0.92 ± 0.09 %). Compared to initial aqueous dispersions, reconstituted spray dried formulations maintained their nanosize and paclitaxel content over 7 days at 4⁰C. In A375 melanoma xenograft mouse model, the tumor volumes were significantly smaller for mice treated with PTX-SLNs compared to the control group. Furthermore, tumor volumes were significantly smaller for mice treated with PTX-SLNs compared to those treated with PTX-micelles and PTX-liposomes. These studies demonstrate the potential of stable PTX-SLNs for targeted delivery in cancer.
Libros sobre el tema "Nanocarrier Liposoma"
1
Weissig, Volkmar. Liposomes : Methods and Protocols, Volume 1: Pharmaceutical Nanocarriers. Humana Press, 2016.
Buscar texto completoCapítulos de libros sobre el tema "Nanocarrier Liposoma"
1
Suntres, Zacharias E. y Abdelwahab Omri. "The Role of Liposomal Antioxidants in Oxidative Stress". En Nanocarrier Technologies, 191–205. Dordrecht: Springer Netherlands, 2006. http://dx.doi.org/10.1007/978-1-4020-5041-1_11.
Texto completo
2
Palma Abriata, Juliana, Marcela Tavares Luiz, Giovanni Loureiro Raspantini, Patrícia Mazureki Campos y Juliana Maldonado Marchetti. "Liposomal Drug Carriers". En Nanocarriers for Brain Targeting, 349–76. Includes bibliographical references and index.: Apple Academic Press, 2019. http://dx.doi.org/10.1201/9780429465079-12.
Texto completo
3
Le, Ngoc Thuy Trang, Linh Phuong Tran Pham, Diem Huong Tran Nguyen, Ngoc Hoang Le, Tuong Vi Tran, Cuu Khoa Nguyen y Dai Hai Nguyen. "Liposome-Based Nanocarrier System for Phytoconstituents". En Novel Drug Delivery Systems for Phytoconstituents, 45–68. Boca Raton : Taylor & Francis, 2020. | “A CRC title, part of the Taylor & Francis imprint, a member of the Taylor & Francis Group, the academic division of T&F Informa plc.”: CRC Press, 2019. http://dx.doi.org/10.1201/9781351057639-3.
Texto completo
4
Sonju, Jafrin Jobayer, Achyut Dahal y Seetharama D. Jois. "Liposome Nanocarriers for Peptide Drug Delivery". En Peptide Therapeutics, 203–35. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-04544-8_6.
Texto completo
5
Sadhu, Piyushkumar K., Nirmal Shah y Hiral M. Manani. "Liposomes: As a Potential Drug Carrier". En Nanocarriers: Drug Delivery System, 303–26. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-4497-6_12.
Texto completo
6
Borin, D. B. y R. C. V. Santos. "A Brief Account of Liposomes for Brain Delivery". En Nanocarriers for Brain Targeting, 333–48. Includes bibliographical references and index.: Apple Academic Press, 2019. http://dx.doi.org/10.1201/9780429465079-11.
Texto completo
7
Phillips, William, Beth Goins y Ande Bao. "Long-Circulating Liposomes with Attached Diagnostic Moieties: Application for Gamma and MR Imaging". En Multifunctional Pharmaceutical Nanocarriers, 431–56. New York, NY: Springer New York, 2008. http://dx.doi.org/10.1007/978-0-387-76554-9_15.
Texto completo
8
Dragićević, Nina. "Lipid-Based Vesicles (Liposomes) as Skin Delivery Systems". En Invasomes as Drug Nanocarriers for Innovative Pharmaceutical Dosage Forms, 31–108. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9781003187332-2.
Texto completo
9
Jain, Anamika, Laxmikant Gautam, Nikhar Vishwakarma, Rajeev Sharma, Nishi Mody, Surbhi Dubey y Suresh P. Vyas. "Emergence of Polymer-Lipid Hybrid Systems in Healthcare Scenario". En Research Anthology on Synthesis, Characterization, and Applications of Nanomaterials, 115–37. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-8591-7.ch006.
Texto completoResumen
Nanotechnology has drawn the attention of many researchers for the delivery of therapeutics used in various medical applications. Liposomes and polymeric nanoparticles represent promising nanocarriers that efficiently encapsulate drugs, which prevents their degradation along with the control and sustained drug release. Despite the many advantages of these formulations, some of the drawbacks associated with them limit their application to a certain extent. Therefore, there is need for a novel nanocarrier that possesses all of their individual advantages and excludes their drawbacks. Currently, researchers are focused on developing a novel platform that is a hybrid of a polymeric and liposomal-based carrier that combines the peculiarity of both and excludes their shortcomings. Lipid hybrid polymer nanoparticles (LPNs) contain the hydrophobic biodegradable polymeric core surrounded by a lipid layer for intensification of biocompatibility. This chapter includes an introduction of LPNs along with their advantages, composition, and method of preparation.
10
Jain, Anamika, Laxmikant Gautam, Nikhar Vishwakarma, Rajeev Sharma, Nishi Mody, Surbhi Dubey y Suresh P. Vyas. "Emergence of Polymer-Lipid Hybrid Systems in Healthcare Scenario". En Multifunctional Nanocarriers for Contemporary Healthcare Applications, 448–70. IGI Global, 2018. http://dx.doi.org/10.4018/978-1-5225-4781-5.ch017.
Texto completoResumen
Nanotechnology has drawn the attention of many researchers for the delivery of therapeutics used in various medical applications. Liposomes and polymeric nanoparticles represent promising nanocarriers that efficiently encapsulate drugs, which prevents their degradation along with the control and sustained drug release. Despite the many advantages of these formulations, some of the drawbacks associated with them limit their application to a certain extent. Therefore, there is need for a novel nanocarrier that possesses all of their individual advantages and excludes their drawbacks. Currently, researchers are focused on developing a novel platform that is a hybrid of a polymeric and liposomal-based carrier that combines the peculiarity of both and excludes their shortcomings. Lipid hybrid polymer nanoparticles (LPNs) contain the hydrophobic biodegradable polymeric core surrounded by a lipid layer for intensification of biocompatibility. This chapter includes an introduction of LPNs along with their advantages, composition, and method of preparation.
Actas de conferencias sobre el tema "Nanocarrier Liposoma"
1
Zhu, Dan, Zhuyuan Wang, Shenfei Zong, Xin Wu, Yuwei Pei, Peng Chen, Xueqin Ma y Yiping Cui. "Liposome-silver Nanoparticles Hybrid as a SERS Traceable Drug Nanocarrier". En JSAP-OSA Joint Symposia. Washington, D.C.: OSA, 2013. http://dx.doi.org/10.1364/jsap.2013.19p_d4_6.
Texto completo
2
Chernenko, T., R. Sawant, L. Quintero, V. Torchilin, M. Diem, P. M. Champion y L. D. Ziegler. "Non-Invasive Imaging of Modified Liposomal Pharmaceutical Nanocarriers by Raman Microscopy". En XXII INTERNATIONAL CONFERENCE ON RAMAN SPECTROSCOPY. AIP, 2010. http://dx.doi.org/10.1063/1.3482503.
Texto completo
3
Grafals, Nilmary, Blanca I. Quiñoes-Diaz, Janixa Del Valle, Gabriel L. Barletta-Bonano y Pablo E. Vivas-Mejía. "Abstract 4409: Developing brain tumor-specific gold-liposomal nanocarriers for a noninvasive delivery of microRNA inhibitors". En Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4409.
Texto completo
4
Halevas, E., T. A. Papadopoulos, A. Hatzidimitriou, D. Reid, A. Salifoglou y G. Litsardakis. "Synthesis, structural, physical and chemical characterization of hybrid magnetic liposome nanocarriers of novel antioxidants for targeted drug delivery". En 2017 IEEE International Magnetics Conference (INTERMAG). IEEE, 2017. http://dx.doi.org/10.1109/intmag.2017.8007873.
Texto completo
5
Sarker, Sunandita, Yiannis S. Chatzizisis, Srivatsan Kidambi y Benjamin S. Terry. "Design and Development of a Novel Drug Delivery Catheter for Atherosclerosis". En 2018 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2018. http://dx.doi.org/10.1115/dmd2018-6869.
Texto completoResumen
Atherosclerosis is a chronic progressive cardiovascular disease that results from plaque formation in the arteries. It is one of the leading causes of death and loss of healthy life in modern world. Atherosclerosis lesions consist of sub-endothelial accumulations of cholesterol and inflammatory cells [1]. However, not all lesions progress to the final stage to cause catastrophic ischemic cardiovascular events [2]. Early identification and treatment of high-risk plaques before they rupture, and precipitate adverse events constitutes a major challenge in cardiology today. Numerous investigations have confirmed that atherosclerosis is an inflammatory disease [3] [4] [5]. This confirmation has opened the treatment of this disease to many novel anti-inflammatory therapeutics. The use of nanoparticle-nanomedicines has gained popularity over recent years. Initially approved as anticancer treatment therapeutics [6], nanomedicine also holds promise for anti-inflammatory treatment, personalized medicine, target-specific treatment, and imaging of atherosclerotic disease [7]. The primary aim of this collaborative work is to develop and validate a novel strategy for catheter-directed local treatment of high-risk plaque using anti-inflammatory nanoparticles. Preselected drugs with the highest anti-inflammatory efficacy will be incorporated into a novel liposome nanocarrier, and delivered in-vivo through a specially designed catheter to high-risk atherosclerotic plaques. The catheter has specially designed perfusion pores that inject drug into the blood stream in such a controlled manner that the streamlines carry the nanoparticles to the stenotic arterial wall. Once the particles make it to the arterial wall, they can be absorbed into the inflamed tissue. In this paper, we discuss the design and development of an atraumatic drug delivery catheter for the administration of lipid nanoparticles.
6
Ferreira, Rodrigo, Christian Maibohm, Oscar F. Silvestre, Rosa Romero, Helder Crespo y Jana B. Nieder. "Few-Cycle Laser for the in Vitro Study of Cellular Bioenergetics during Therapeutic Treatment with the Anticancer Drug Doxorubicin in its Free and Liposomal Nanocarrier Form". En 2019 Conference on Lasers and Electro-Optics Europe & European Quantum Electronics Conference (CLEO/Europe-EQEC). IEEE, 2019. http://dx.doi.org/10.1109/cleoe-eqec.2019.8871603.
Texto completo